Abstracts tagged "Lipids"

Abstract Number: 1783 • 2015 ACR/ARHP Annual Meeting
Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain
Cristina Arriens¹, Carlos Rodriguez-Navas², David R. Karp¹, Jeffrey McDonald² and Chandra Mohan³, ¹Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ²Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: A comprehensive metabolomic screen comparing sera from patients with systemic lupus erythematosus (SLE) to healthy controls (HC) indicated a relative deficiency in omega-3 fatty…
Abstract Number: 2270 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis
Karen Soikkeli¹ and Glenn Ehresmann², ¹Graduate Nursing (Family Nurse Practitioner Program), Azusa Pacific University, Diamond Bar, CA, ²Rheumatology, Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, Los Angeles, CA
Background/Purpose: Despite the fact that patients with rheumatoid arthritis (RA) experience a 50-60% increased risk of developing cardiovascular disease (CVD), substantial gaps remain in the…
Abstract Number: 1063 • 2014 ACR/ARHP Annual Meeting
Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting
Kashif Jafri¹, Lynne Taylor², Nehal N. Mehta³, Melissa Nezamzadeh⁴, Joshua Baker⁵ and Alexis Ogdie⁶, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁶Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality. It is unclear, however, whether this knowledge has translated into…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 2465 • 2014 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α
Ikuko Masuda^1,2, Kodo Okada³, Hisashi Yamanaka⁴ and Shigeki Momohara⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, ³SANSHO, Co. Ltd., Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on…
Abstract Number: 2305 • 2014 ACR/ARHP Annual Meeting
Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice
Ashwini Komarla¹ and Alexis Ogdie², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose Cardiovascular disease is the leading cause of mortality in the rheumatoid arthritis (RA) population. However, cardiovascular risk factors such as hyperlipidemia are undertreated in…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function
Silvia Rollefstad¹, Bente Halvorsen², Tonje Skarpengland², Sella Provan³, Tore K. Kvien⁴ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…
Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting
Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Ashwini Komarla¹ and Alexis Ogdie², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…
Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting
Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Silvia Rollefstad¹, Ingvild Eeg², Ida K. Haugen², Inge C. Olsen³, Nina Østerås⁴, Barbara Christensen², Hilde Berner Hammer⁵, Lars Nordsletten⁶, Bård Natvig⁷, Tore K. Kvien⁸ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway, ⁷General Practice, Oslo University, Oslo, Norway, ⁸Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…
Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting
Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting
The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis
Hidetake Nagahara¹, Masataka Kohno¹, Ken Murakami¹, Aihiro Yamamoto¹, Takahiro Seno¹, Wataru Fujii¹, Kazuki Fujioka¹, Yuji Kukida¹, Ryo Oda², Hiroyoshi Fujiwara² and Yutaka Kawahito¹, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan
Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…
Abstract Number: 1166 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice
Hajime Kono¹, Tamiko Yanagida², Kurumi Asako¹, Toshihiro Nanki¹, Hirotoshi Kikuchi¹, Akiko Okamoto¹, Akiko Onda³ and Maki Takayama¹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Depart ment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis is a chronic metabolic disease of inflammatory processes. Immune cells including monocytes are recruited to the subintimal lesion of the vascular wall and…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].